Breaking News, Promotions & Moves

XyloCor Therapeutics Names New President and CEO

John Tucker brings more than 20 years of leadership experience in the biotechnology and life sciences industries.

XyloCor Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease, has appointed John Tucker as President and Chief Executive Officer (CEO), effective immediately.

Tucker brings more than 20 years of leadership experience in the biotechnology and life sciences industries, with a proven track record of advancing clinical programs, building high-performing teams, and driving strategic growth. He succeeds the Company’s current interim leadership, will join the Board of Directors and assumes both roles effective immediately.

Prior to joining XyloCor, Tucker served as CEO of scPharmaceuticals. Prior to that, he served as CEO of Alcresta Therapeutics.

“XyloCor is at a pivotal moment in its evolution,” said Tucker. “With a promising pipeline and a deeply committed team, we are well positioned to transform the treatment landscape for patients with cardiovascular disease. I am honored to lead the Company into its next chapter and look forward to accelerating our clinical programs, strengthening our partnerships and delivering long-term value to both patients and shareholders.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters